ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates [Yahoo! Finance]
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: Yahoo! Finance
of approximately $261M as of December 31, 2025, provide expected cash runway at least to 2028 Anticipated near-term catalysts include LOTIS-7 complete enrollment in first half of 2026 and LOTIS-5 Phase 3 topline data in second quarter 2026 Additional anticipated catalysts include full LOTIS-5 and LOTIS-7 results by end of 2026, with potential compendia inclusions in first half of 2027 and LOTIS-5 regulatory approvals to follow LAUSANNE, Switzerland Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today provided corporate updates and highlights from its ZYNLONTA® clinical program. "During 2025, we delivered meaningful progress across our ZYNLONTA clinical program and extended our expected cash runway at least to 2028," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This year, we look forward to multiple clinical catalysts including full results from our
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCTPR Newswire
- Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? [Yahoo! Finance]Yahoo! Finance
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCTGlobeNewswire
- ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate UpdatesPR Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCTPR Newswire
ADCT
Earnings
- 11/10/25 - Beat
ADCT
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form 8-K
- 12/15/25 - Form EFFECT
- ADCT's page on the SEC website